by Kausalya Murthy | Jul 17, 2018 | Science |
Last week, our blog featured a recap of the first of two C. elegans topic meetings – CE Neuro 2018 – that some members of Perlara’s worm team attended last month. In this post, Hillary and I share our experiences at the CE Aging 2018 conference. Also...
by Feba Sam | Jul 10, 2018 | Science |
At Perlara, we work to find therapeutics for rare genetic diseases. We develop and use immunoassays, phase contrast imaging, as well as enzymatic assays, in order to screen thousands of compounds and obtain hits from cell readouts to complement our model organism...
by Sangeetha Iyer | Jul 9, 2018 | Science |
Perlara’s worm team recently attended two C. elegans neuroscience conferences – CE Neuro 2018 & CE Aging 2018 – both held at the University of Wisconsin, Madison. This post recaps Zach and my time at the CE Neuro 2018 conference, which focused on...
by Julide Bilen | Jun 7, 2018 | PMM2-CDG |
An update on the development of PMM2 Drosophila models, and our work to design high throughput drug screen for PMM2 deficiency — Phosphomannomutase 2 deficiency (PMM2-CDG) is the most common type of congenital disorder of glycosylation resulting from a defect in...
by Zach Parton | May 17, 2018 | Science |
In 2016, Perlara and Wylder Nation launched a PerlQuest to find a cure for Niemann-Pick Type A (NPA). We have also been developing simple organism disease models for Niemann-Pick Type C (NPC) as a part of our research collaboration with Novartis. An interesting...
